A federal judge in Delaware has ruled in favor of Exelixis in its Cabometyx patent fight with MSN Laboratories, effectively ...

Leerink Partners analyst Andrew Berens has maintained their neutral stance on EXEL stock, giving a Hold rating today. Andrew Berens has given ...

The Delaware District Court ruled in EXEL's favor, rejecting MSN's challenge to three patents related to cabozantinib.

RBC Capital analyst Gregory Renza maintained a Buy rating on Exelixis (EXEL – Research Report) yesterday and set a price target of ...

Exelixis (EXEL) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate ...

Exelixis, Inc. (NASDAQ:EXEL – Get Free Report)’s stock price reached a new 52-week high during mid-day trading on Tuesday after Bank of America raised their price target on the stock from $30.00 to ...

Indian benchmark indices Nifty 50 and Sensex ended lower in the previous trade session. Nifty 50 closed at 25,057.35, while Sensex ended at 81,820.12. Overnight, Wall Street indices tumbled from ...